drugset / Trial / NCT01829971
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Phase 1
Terminated
155 enrolled
Mirna Therapeutics, Inc.
Cancer Prevention Research Institute of Texas · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.
Timeline
- Start
- 2013-04
- Primary completion
- 2017-03
- Completion
- 2017-05
Outcome
Outcome not reported
Stopped: “Five immune related serious adverse events”
Publications
- Lucibello G, Mograbi B, Milano G, Hofman P, Brest P. PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends Mol Med. 2021 Sep;27(9):868-881. doi: 10.1016/j.molmed.2021.06.005. Epub 2021 Jun 26.
- Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O'Neill V, Beg MS. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020 May;122(11):1630-1637. doi: 10.1038/s41416-020-0802-1. Epub 2020 Apr 2.